The 340B Drug Pricing Program, Hospital Prices, and Competition in Commercial Markets

OBJECTIVE: To examine whether hospital eligibility for the 340b drug pricing program reduces prices for clinician-administered drugs in commercial insurance markets and whether effects vary by market competition. STUDY SETTING AND DESIGN: We conducted a quasi-experimental study using a regression discontinuity design that leverages the federal eligibility threshold for 340B participation (disproportionate share hospital [DSH] percentage > 11.75%). The study included non-profit and public acute care hospitals that billed for clinician-administered drugs in the outpatient setting between 2012 and 2014. The primary outcome was hospital-insurer negotiated unit prices for high-spending outpatient drugs. Secondary outcomes included drug volume and revenue. DATA SOURCES AND ANALYTIC SAMPLE: We analyzed secondary data from the Health Care Cost Institute (HCCI), which includes claims from three national commercial insurers linked to hospital-level characteristics from the Hospital Cost Report Information System (HCRIS) and provider identifiers from the National Plan and Provider Enumeration System (NPPES). The analytic sample comprised 637 hospitals billing 148,037 clinician-administered drug claims for the five drugs with highest total spending. PRINCIPAL FINDINGS: Hospital 340B eligibility was associated with a $605 reduction (95% CI: -934 to -276) in median unit drug prices, a 25% decrease relative to the mean price among ineligible hospitals at the threshold ($2387). Effects were concentrated in competitive markets (Herfindahl-Hirschman Index [HHI] ≤ 1800), where eligibility was associated with a $793 reduction (95% CI: -1197 to -388), a 32% decrease. In highly concentrated markets, effects were small and statistically insignificant. Price reductions were offset by non-significant increases in drug volume (25%) and neutral effects on drug revenue. CONCLUSIONS: Hospital 340B eligibility reduced commercial drug prices only in competitive markets. These findings suggest that market competition is critical for ensuring that policy-driven hospital cost savings are shared with payers and patients.